Crohn-betegség: vizsgálatok itt: Spanyolország
37 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
- Where
- Badalona, Barcelona, Ferrol, Madrid, Pontevedra, Santa Cruz de Tenerife, Torrejón de Ardoz, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 567 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Where
- Badalona, Barcelona, Ferrol, Madrid, Pontevedra, Santa Cruz de Tenerife, Torrejón de Ardoz, Valencia, Zaragoza
- Életkor
- 16 év to 80 év
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00 - 2. fázisTaking peopleA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- Where
- Ferrol, Lleida, Madrid, Majadahonda, Sevilla, Valencia
- Életkor
- 18 év to 85 év
- People
- 385 worldwide
- Run by
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00 - 3. fázisTaking peopleMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Where
- Barcelona, Ferrol, Gijón, Madrid, Oviedo, Pamplona, Seville, Valencia
- Életkor
- 18 év to 70 év
- People
- 290 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00 - 3. fázisTaking peopleA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Córdoba, Sabadell, Valencia
- Életkor
- 2 év to 17 év
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00 - 3. fázisTaking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Santiago de Compostela, Valencia
- Életkor
- 3 év to 64 év
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - 2/3. fázisTaking peopleA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Barcelona, Gijón, Girona, Madrid, Santiago de Compostela, Sevilla, Valencia
- Életkor
- 18 év and over
- People
- 1092 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00 - 3. fázisTaking peopleA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Alicante, Barcelona, Ferrol, Gijón, Girona, Madrid, Navarra, Santiago de Compostela, Seville
- Életkor
- 18 év and over
- People
- 530 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07499232 - 3. fázisTaking peopleA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Ferrol, Gijón, Madrid, Sevilla, Valencia, Vigo
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00 - No phaseNot yet taking people in SpanyolországA Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
- Where
- Santiago de Compostela
- Életkor
- 18 év and over
- People
- 200
- Run by
- Janssen-Cilag, S.A.
See details and how to joinNCT07848737 - 2. fázisTaking peopleA Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
- Where
- Barcelona, Madrid, Sevilla
- Életkor
- 18 év to 75 év
- People
- 99 worldwide
- Run by
- Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00 - 4. fázisTaking peopleA study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indication
- Where
- Madrid
- People
- 16 worldwide
- Run by
- Eli Lilly & Co.
See details and how to join2025-522362-78-00 · EU 2025-522362-78-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Alcorcón, Fuenlabrada, Madrid, Majadahonda, Zaragoza
- Életkor
- 16 év to 80 év
- People
- 425 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00 - 3. fázisTaking peopleAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Gijón, Huelva, Madrid, Ourense
- Életkor
- 16 év to 80 év
- People
- 980 worldwide
- Run by
- Sanofi
See details and how to joinNCT07184931 - 3. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Where
- Esplugues De Llobregat, Ferrol, Madrid, Málaga
- Életkor
- 2 év to 17 év
- People
- 110 worldwide
- Run by
- AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00 - 3. fázisTaking peopleA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- Where
- Córdoba, Galdakao, Madrid, Santa Cruz de Tenerife, Santander, Valencia, Valladolid
- Életkor
- 16 év to 80 év
- People
- 600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00 - 2. fázisTaking peopleA clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
- Where
- Barcelona, Oviedo, Pamplona, Sabadell, Santander
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00 - 3. fázisTaking peopleA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Where
- Ferrol, Madrid, Sevilla, Valencia
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00 - 3. fázisTaking peopleA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Where
- Córdoba, Esplugues de Llobregat, Sabadell, Valencia
- Életkor
- 2 év to 19 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT04844606 - 3. fázisTaking peopleA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Where
- Córdoba, Sabadell, Valencia
- Életkor
- 2 év to 17 év
- People
- 90 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00 - No phaseNot yet taking people in SpanyolországArtificial Intelligence For Outcomes Research in Crohn's Disease: Digital Pathology Assessment of Fibrosis and Association With Patient History and Clinical Outcomes
- Where
- Seville
- Életkor
- 18 év to 80 év
- People
- 100
- Run by
- PharmaNest, Inc
See details and how to joinNCT07795476 - 2. fázisTaking peopleStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Where
- Fuenlabrada, Madrid, Santiago de Compostela, Sevilla, Valencia, Vigo
- Életkor
- 18 év to 75 év
- People
- 590 worldwide
- Run by
- AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00 - 3. fázisTaking peopleCrohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
- Where
- Alicante, Barcelona, Ferrol, Gijón, Girona, Pamplona, Santiago de Compostela, Sevilla, Torrejón de Ardoz
- Életkor
- 18 év and over
- People
- 302 worldwide
- Run by
- Janssen Cilag International
See details and how to join2025-521590-13-00 · EU 2025-521590-13-00 - 3. fázisTaking peopleA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- Where
- Ferrol, Madrid, Sevilla, Valencia
- Életkor
- 2 év to 17 év
- People
- 70 worldwide
- Run by
- Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00 - No phaseTaking peopleProspective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
- Where
- Galdakao
- Életkor
- 16 év to 35 év
- People
- 10 000 worldwide
- Run by
- GLSMED Learning Health S.A.
See details and how to joinNCT07316621